REXO1L6P
associated omics dataQ-omics provides the consensus-scored REXO1L6P profile across patient tissues and cancer cell-line models. REXO1L6P expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in KIRC.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REXO1L6P — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes REXO1L6P survival associations across molecular data types. REXO1L6P RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REXO1L6P RNA expression–survival associations across cancer types. High REXO1L6P expression shows unfavorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for REXO1L6P RNA expression.
